These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22843946)

  • 1. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.
    Almhanna K; El-Rayes B; Sethi S; Dyson G; Heilbrun L; Philip PA; Sarkar F
    Anticancer Res; 2012 Aug; 32(8):3559-63. PubMed ID: 22843946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
    Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
    J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Köhne CH; De Greve J; Hartmann JT; Lang I; Vergauwe P; Becker K; Braumann D; Joosens E; Müller L; Janssens J; Bokemeyer C; Reimer P; Link H; Späth-Schwalbe E; Wilke HJ; Bleiberg H; Van Den Brande J; Debois M; Bethe U; Van Cutsem E
    Ann Oncol; 2008 May; 19(5):920-6. PubMed ID: 18065406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
    Cassinello J; Alvarez JV; López MJ; Pujol E; Colmenarejo A; Segovia F; Marcos F; Filipovich E; Arcediano A; Castro IG
    Clin Colorectal Cancer; 2006 Mar; 5(6):429-35. PubMed ID: 16635282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
    Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
    Suzuki N; Hazama S; Nagasaka T; Tanioka H; Iwamoto Y; Negoro Y; Yamauchi M; Kobayashi M; Okuda H; Fujishima N; Nishimura T; Yamanaka N; Toyota K; Mori Y; Nakagami Y; Shimokawa M; Nagano H; Okajima M
    Int J Clin Oncol; 2019 Oct; 24(10):1223-1230. PubMed ID: 31144145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Renouf DJ; Welch S; Moore MJ; Krzyzanowska MK; Knox J; Feld R; Liu G; MacKay H; Petronis J; Wang L; Chen E
    Cancer Chemother Pharmacol; 2012 May; 69(5):1339-44. PubMed ID: 22349811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
    Chen EY; Blanke CD; Haller DG; Benson AB; Dragovich T; Lenz HJ; Robles C; Li H; Mori M; Mattek N; Sanborn RE; Lopez CD
    Am J Clin Oncol; 2018 Dec; 41(12):1193-1198. PubMed ID: 29782360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
    J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
    Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
    Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
    Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.